Myxedema Coma Summary

Emergency Signs

  • Altered mental status
  • Hypothermia (<35°C)
  • Bradycardia
  • Hypotension
  • Hypoventilation

Key Labs

  • ↑ TSH (markedly elevated)
  • ↓ Free T4 (very low)
  • Hyponatremia
  • Hypoglycemia
  • Respiratory acidosis

Immediate Treatment

  • IV Levothyroxine loading
  • Hydrocortisone IV
  • Passive rewarming
  • ICU admission
  • Treat precipitating cause

Medication Doses

  • Levothyroxine: 200-500μg IV load
  • Hydrocortisone: 100mg IV q8h
  • Consider T3: 10μg IV q8h

Critical Avoidances

  • No active rewarming
  • Avoid sedation
  • Slow electrolyte correction
  • Cautious fluid administration

Myxedema Coma

A life-threatening complication of severe hypothyroidism

Overview

Myxedema coma is the extreme manifestation of hypothyroidism, representing a medical emergency with mortality rates of 30-50%. It is characterized by altered mental status and hypothermia in the setting of severe hypothyroidism, often precipitated by an acute illness or stressor in patients with long-standing untreated or inadequately treated hypothyroidism.

MEDICAL EMERGENCY

Myxedema coma requires immediate ICU admission and aggressive management. Delayed treatment significantly increases mortality risk.

Clinical Presentation

Classic Triad

Additional Features

Cardiovascular

  • Bradycardia
  • Hypotension
  • Reduced cardiac output
  • Pericardial effusion

Respiratory

  • Hypoventilation
  • Hypercapnia
  • Respiratory acidosis
  • Possible need for mechanical ventilation

Neurological

  • Delayed deep tendon reflexes
  • Seizures
  • Psychosis ("myxedema madness")

Metabolic

  • Hyponatremia
  • Hypoglycemia
  • Anemia
  • Elevated CK

Key Physical Findings

  • Cool, pale, dry skin
  • Periorbital edema
  • Macroglossia
  • Non-pitting edema (myxedema)
  • Alopecia
  • Loss of lateral eyebrows

Precipitating Factors

Common triggers that can precipitate myxedema coma in patients with hypothyroidism:

Diagnosis

Diagnosis is primarily clinical with laboratory confirmation:

Laboratory Findings

Important Note

Treatment should be initiated immediately based on clinical suspicion without waiting for lab confirmation. Mortality correlates with treatment delay.

Management Protocol

Step 1: Immediate ICU Admission

  • Secure airway and mechanical ventilation if needed
  • Continuous cardiac monitoring
  • Central venous access
  • Arterial line for blood pressure monitoring

Step 2: Thyroid Hormone Replacement

  • IV Levothyroxine loading dose: 200-500μg IV
  • Maintenance: 50-100μg IV daily
  • Consider T3: 10μg IV q8h in severe cases
  • Switch to oral when stable (usually day 3-5)

Step 3: Glucocorticoid Coverage

  • Hydrocortisone 100mg IV q8h
  • Continue until adrenal insufficiency ruled out
  • Gradual taper once stable

Step 4: Supportive Care

  • Passive rewarming (blankets, warm environment)
  • Avoid active rewarming (risk of vasodilation and shock)
  • IV fluids: Cautious administration (risk of CHF)
  • Treat precipitating cause (antibiotics for infection, etc.)

Cardiovascular Management

  • Bradycardia: Usually responds to thyroid replacement
  • Hypotension: Vasopressors if unresponsive to fluids
  • Monitor for arrhythmias during treatment

Metabolic Correction

  • Hyponatremia: Fluid restriction (800-1000ml/day)
  • Hypoglycemia: D50W as needed
  • Correct electrolytes slowly

Respiratory Support

  • Monitor ABG frequently
  • Mechanical ventilation for pCO2 >50mmHg
  • Avoid sedatives if possible

Critical Considerations

  • Avoid sedation (risk of respiratory arrest)
  • Monitor for arrhythmias during treatment
  • Correct electrolytes slowly
  • Adrenal insufficiency may coexist (always give steroids initially)
  • Mortality: 30-50% despite treatment

Prognosis and Follow-up

Poor Prognostic Factors

  • Advanced age
  • Persistent hypotension
  • Severe hypothermia (<30°C)
  • Bradycardia <40 bpm
  • Sepsis as precipitant
  • Treatment delay >48 hours

Long-term Management